Sarepta Therapeutics (SRPT) Assets Average (2011 - 2026)
Sarepta Therapeutics' quarterly Assets Average came in at $3.3 billion in Q1 2026, down 12.11% year-on-year from $3.7 billion in Q1 2025, and down 4.6% quarter-over-quarter from $3.4 billion in Q4 2025.
Sarepta Therapeutics has reported Assets Average for 16 years, with the latest figure at $3.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets Average fell 12.11% year-over-year to $3.3 billion; the trailing twelve-month figure through Mar 2026 stood at $3.3 billion (down 12.11% YoY), and the FY2025 full-year result was $3.7 billion, up 1.18% from the prior year.
- Assets Average for Q1 2026 stood at $3.3 billion, down from $3.4 billion in the prior quarter.
- The five-year high for Assets Average was $3.8 billion in Q4 2024, with the low at $3.0 billion in Q2 2022.
- Average Assets Average over 5 years is $3.3 billion, with a median of $3.2 billion recorded in 2024.
- Year-over-year, Assets Average grew 18.65% in 2024 and dropped 12.11% in 2026.
- Tracing SRPT's Assets Average over 5 years: stood at $3.1 billion in 2022, then gained by 1.43% to $3.2 billion in 2023, then gained by 18.65% to $3.8 billion in 2024, then slipped by 9.52% to $3.4 billion in 2025, then fell by 4.6% to $3.3 billion in 2026.
- The last three Assets Average figures came in at $3.3 billion (Q1 2026), $3.4 billion (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | 3.26 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.26 Bn |
| Dec 31, 2025 | 3.42 Bn |
| Sep 30, 2025 | 3.59 Bn |
| Jun 30, 2025 | 3.57 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Dec 31, 2024 | 3.78 Bn |
| Sep 30, 2024 | 3.51 Bn |
| Jun 30, 2024 | 3.32 Bn |
| Mar 31, 2024 | 3.24 Bn |
| Dec 31, 2023 | 3.19 Bn |
| Sep 30, 2023 | 3.12 Bn |
| Jun 30, 2023 | 3.09 Bn |
| Mar 31, 2023 | 3.09 Bn |
| Dec 31, 2022 | 3.14 Bn |
| Sep 30, 2022 | 3.08 Bn |
| Jun 30, 2022 | 3.03 Bn |
| Mar 31, 2022 | 3.10 Bn |
| Dec 31, 2021 | 2.91 Bn |
| Sep 30, 2021 | 2.71 Bn |
| Jun 30, 2021 | 2.76 Bn |
| Mar 31, 2021 | 2.87 Bn |
| Dec 31, 2020 | 2.88 Bn |
| Sep 30, 2020 | 2.83 Bn |
| Jun 30, 2020 | 2.92 Bn |
| Mar 31, 2020 | 2.39 Bn |
| Dec 31, 2019 | 1.76 Bn |
| Sep 30, 2019 | 1.73 Bn |
| Jun 30, 2019 | 1.86 Bn |
| Mar 31, 2019 | 1.80 Bn |
| Dec 31, 2018 | 1.41 Bn |
| Sep 30, 2018 | 1.22 Bn |
| Jun 30, 2018 | 1.27 Bn |
| Mar 31, 2018 | 1.30 Bn |
| Dec 31, 2017 | 1.05 Bn |
| Sep 30, 2017 | 625.21 Mn |
| Jun 30, 2017 | 480.84 Mn |
| Mar 31, 2017 | 467.82 Mn |
| Dec 31, 2016 | 455.71 Mn |
| Sep 30, 2016 | 345.69 Mn |
| Jun 30, 2016 | 208.72 Mn |
| Mar 31, 2016 | 243.57 Mn |
| Dec 31, 2015 | 229.27 Mn |
| Sep 30, 2015 | 208.23 Mn |
| Jun 30, 2015 | 237.21 Mn |
| Mar 31, 2015 | 268.87 Mn |
| Dec 31, 2014 | 307.05 Mn |
| Sep 30, 2014 | 328.18 Mn |
| Jun 30, 2014 | 306.35 Mn |
| Mar 31, 2014 | 283.48 Mn |
| Dec 31, 2013 | 298.02 Mn |
| Sep 30, 2013 | 244.06 Mn |
| Jun 30, 2013 | 188.49 Mn |
| Mar 31, 2013 | 199.17 Mn |
| Mar 31, 2012 | 50.51 Mn |
| Dec 31, 2011 | 57.73 Mn |
| Sep 30, 2011 | 68.01 Mn |